Muscle loss on a GLP-1, and what the scans actually found

Weight reduction can include changes in both fat and lean tissue. These body-composition substudies help describe those changes in defined trial populations. They do not establish that every patient preserves muscle or develops weakness. Interpretation needs the absolute changes, the comparison group and the limits of what a scan measures.

What the labels claim, exactly

Both use the same construction, and it is a careful one. Wegovy: “Semaglutide lowers body weight with greater fat mass loss than lean mass loss.” Zepbound: “Tirzepatide lowers body weight with greater fat mass loss than lean mass loss.” Greater than, not instead of. Neither sentence claims lean mass is preserved, and reading it as though it did is where most of the confusion starts. The mechanism behind both is in How GLP-1 drugs actually work, and what that explains.

The tirzepatide substudy, including its placebo arm

SURMOUNT-1 ran a DXA substudy: 160 participants completed scans at baseline and week 72, 124 on tirzepatide and 36 on placebo, mean weight 102.5 kg and BMI 38.0. At week 72 body weight was down 21.3%, fat mass 33.9% and lean mass 10.9% on tirzepatide, against 5.3%, 8.2% and 2.6% on placebo.

Both the amount and the proportion matter. The authors report 74% of the reduction as fat mass and 26% as lean mass with tirzepatide, compared with 75% and 25% with placebo. Those are similar proportions in this substudy, alongside different total losses. The comparison does not establish identical outcomes or make an individual change in lean mass clinically unimportant.

The semaglutide analysis measured something slightly different

The STEP 1 body composition analysis scanned 140 participants — 95 on semaglutide, 45 on placebo, mean weight 98.4 kg, BMI 34.8. Body weight fell 15.0% against 3.6% on placebo. Total fat mass fell 19.3%, regional visceral fat 27.4%, and total lean body mass 9.7%.

But its headline finding is expressed as a proportion of the body rather than of the loss, and that flips the sign. Lean body mass as a share of total body mass rose by 3.0 percentage points; fat mass fell 3.5 points as a share. The lean-to-fat ratio rose from 1.34 at baseline by 0.23 overall — and by 0.41 in those losing 15% or more of their weight, against 0.03 in those losing less. On that measure the people who lost the most weight came out with the most favourable composition, not the least.

Questions about nutrition, activity and follow-up

Ask how nutrition and activity will be considered during treatment. CDC adult guidance includes muscle-strengthening activity, but the appropriate routine and any nutrition target need to account for your health and abilities. The DXA substudy did not establish that a specific exercise or supplement program prevents lean-mass loss.

Our research records 13 of 87 services mentioning bloodwork and 60 describing support between visits. Missing published information does not prove that a service performs no assessment. Use Thirteen things a GLP-1 service should tell you before you pay to ask what is actually offered, and examine claims about muscle-protection products separately in GLP-1 supplements: what the label says, and what the evidence says.

For the practical conversation, read what to discuss about strength and everyday function. It explains how to describe an activity that changed, ask whether assessment is appropriate and bring functional goals into an online consultation.

The other thing worth knowing is what happens to composition afterwards. Weight regained after stopping is not guaranteed to return in the same proportions it left, which is one more reason the decision at the end of the first year deserves more thought than the monthly price suggests — What happens when you stop and The first year on a GLP-1, in the order things actually happen.